Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLP 2 analogue
FE203799 · 1 trial · 1 indication
Adverse events as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| FE203799 5 mg | EXPERIMENTAL | FE203799 5 mg subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| FE203799 | DRUG | FE203799 5 mg subcutaneous once weekly |
Inclusion Criteria: 1. Males and females with SBS secondary to surgical resection of the small intestine, with or without an intact colon. 2. 18-80 years of age 3. Average faecal wet weight excretion of ≥1500 g/day during the baseline balance study 4. Average urine production \<2000 mL/day during t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Teduglutide |
| Ironwood Pharmaceuticals, Inc. Class A | IRWD | 2 | PHASE3 | Apraglutide |
| Jaguar Health, Inc. | JAGX | 2 | PHASE2 | Crofelemer |
FE203799 is an investigational small molecule being developed by Ironwood Pharmaceuticals, Inc. for short bowel syndrome (SBS) with intestinal insufficiency. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not described as approved for any use.
FE203799 is being developed for short bowel syndrome with intestinal insufficiency, a gastrointestinal condition in which patients have reduced functional intestine. The completed Phase 1 study was a metabolic balance study in patients with SBS with intestinal insufficiency, conducted in Denmark with eight enrolled participants.
FE203799 is being developed by Ironwood Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker IRWD. Ironwood is the sponsor of the clinical program for this investigational small molecule in short bowel syndrome with intestinal insufficiency.
FE203799 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The program is investigational, and the available information does not indicate that FE203799 has been approved by the FDA or any other regulatory authority.
FE203799 has been evaluated in one completed Phase 1 trial, NCT03408132, titled a metabolic balance study of FE203799 in patients with SBS with intestinal insufficiency. The trial enrolled eight participants in Denmark, included adults 18 years and older of all sexes, and was uncontrolled, without randomization or double blinding.